Summary

The Asia-Pacific hepatitis B infection market is expected to reach USD 6.52 billion by 2031 from USD 4.03 billion in 2023, growing at a CAGR of 6.2% in the forecast period of 2024 to 2031.
Market Segmentation:
Asia-Pacific Hepatitis B Infection Market Segmentation, By Type (Chronic and Acute), By treatment (Vaccine, Antiviral Drugs, Immune Modulator Drugs, and Surgery, By Countries (China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Vietnam, New Zealand, Taiwan, Philippines, and rest of Asia-Pacific)- Industry Trends and Forecast to 2031

Overview of Asia-Pacific Hepatitis B infection Market Dynamics:

Driver

• Increasing prevalence of hepatitis B infections
Restraint

• Side effects and drug resistance

Opportunity

• Advanced research and development for clinical trials

Market Players:

The key market players operating in the Asia-Pacific hepatitis B infection market are listed below:

• Gilead Sciences, Inc.
• GSK plc
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb

ページTOPに戻る

Table of Contents

1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF ASIA-PACIFIC HEPATITIS B INFECTION MARKET 22
1.4 MARKETS COVERED 25
2 MARKET SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 30
2.6 MULTIVARIATE MODELLING 33
2.7 THERAPEUTICS LIFELINE CURVE 34
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.9 DBMR MARKET POSITION GRID 36
2.10 VENDOR SHARE ANALYSIS 37
2.11 SECONDARY SOURCES 38
2.12 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHT 44
4.1 PESTAL ANALYSIS 45
4.2 PORTER FIVE FORCES 46
5 ASIA-PACIFIC HEPATITIS B INFECTION MARKET: REGULATIONS 47
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION 47
5.2 NORTH AMERICA REGULATORY SCENARIO 55
5.3 EUROPE REGULATORY SCENARIO 63
5.4 MIDDLE EAST AND AFRICA REGULATORY SCENARIO 67
5.5 SOUTH AMERICA REGULATORY SCENARIO 72
6 PIPELINE ANALYSIS 77
7 EPIDEMILIOGY 88
8 MARKET OVERVIEW 90
8.1 DRIVERS 92
8.1.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS 92
8.1.2 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS 93
8.1.3 DEVELOPMENT OF COMBINATION THERAPIES FOR HEPATITIS B 94
8.1.4 STRATEGIC INITIATIVES BY COMPANIES FOR HEPATITIS B INFECTION 95
8.2 RESTRAINTS 96
8.2.1 SIDE EFFECTS AND DRUG RESISTANCE 96
8.2.2 INSUFFICIENT VACCINE COVERAGE FOR HEPATITIS B INFECTION 97
8.3 OPPORTUNITY 98
8.3.1 RISING NEW DRUG RELEASES AND INCREASING NEW DRUG PERMITS FOR HEPATITIS B 98
8.3.2 GOVERNMENT PROGRAMS TO RAISE AWARENESS OF HEPATITIS B INFECTION 99
8.3.3 ADVANCED RESEARCH AND DEVELOPMENT FOR CLINICAL TRIALS 100
8.4 CHALLENGES 101
8.4.1 THE COST OF HEPATITIS B TREATMENTS IS HIGH 101
8.4.2 STRINGENT REGULATORY POLICIES AND REGIONAL DISPARITIES IN TREATMENT ACCESS 102
9 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE 103
9.1 OVERVIEW 104
9.2 CHRONIC 107
9.3 ACUTE 107
10 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TREATMENT 108
10.1 OVERVIEW 109
10.2 VACCINE 112
10.2.1 HOSPITAL PHARMACIES 112
10.2.2 DRUGS STORES AND RETAIL PHARMACIES 112
10.2.3 ONLINE PHARMACIES 112
10.3 ANTIVIRAL DRUGS 113
10.3.1 TENOFOVIR ALAFENAMIDE FUMARATE (TAF) 113
10.3.2 TENOFOVIR DISOPROXIL FUMARATE (TDF) 113
10.3.3 ENTECAVIR 113
10.3.4 OTHERS 113
10.4 IMMUNE MODULATOR DRUGS 114
10.4.1 PEGYLATED INTERFERON 114
10.4.2 INTERFERON ALPHA 114
10.5 SURGERY 115
11 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY REGION 116
11.1 ASIA-PACIFIC 118
11.1.1 CHINA 121
11.1.2 INDIA 123
11.1.3 INDONESIA 125
11.1.4 JAPAN 127
11.1.5 VIETNAM 129
11.1.6 PHILIPPINES 131
11.1.7 THAILAND 133
11.1.8 SOUTH KOREA 135
11.1.9 AUSTRALIA 137
11.1.10 SINGAPORE 139
11.1.11 MALAYSIA 141
11.1.12 NEW ZEALAND 143
11.1.13 TAIWAN 145
11.1.14 REST OF ASIA-PACIFIC 147
12 ASIA-PACIFIC HEPATITIS B TREATMENT MARKET: COMPANY LANDSCAPE 148
12.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS 149
14 COMPANY PROFILE 150
14.1 GILEAD SCIENCES, INC. 150
14.1.1 COMPANY SNAPSHOT 150
14.1.2 REVENUE ANALYSIS 150
14.1.3 COMPANY SHARE ANALYSIS 151
14.1.4 PRODUCT PORTFOLIO 151
14.1.5 RECENT DEVELOPMENT 151
14.2 GLAXOSMITHKLINE PLC 153
14.2.1 COMPANY SNAPSHOT 153
14.2.2 REVENUE ANALYSIS 153
14.2.3 COMPANY SHARE ANALYSIS 154
14.2.4 PRODUCT PORTFOLIO 154
14.2.5 RECENT DEVELOPMENT 154
14.3 DYNAVAX TECHNOLOGIES CORPORATION 156
14.3.1 COMPANY SNAPSHOT 156
14.3.2 REVENUE ANALYSIS 156
14.3.3 COMPANY SHARE ANALYSIS 157
14.3.4 PRODUCT PORTFOLIO 157
14.3.5 RECENT DEVELOPMENTS 157
14.4 F. HOFFMAN-LA ROCHE LTD. 159
14.4.1 COMPANY SNAPSHOT 159
14.4.2 REVENUE ANALYSIS 159
14.4.3 COMPANY SHARE ANALYSIS 160
14.4.4 PRODUCT PORTFOLIO 160
14.4.5 RECENT DEVELOPMENTS 160
14.5 BRISTOL-MYERS SQUIBB COMPANY 161
14.5.1 COMPANY SNAPSHOT 161
14.5.2 REVENUE ANALYSIS 161
14.5.3 COMPANY SHARE ANALYSIS 162
14.5.4 PRODUCT PORTFOLIO 162
14.5.5 RECENT DEVELOPMENTS 162
14.6 ARROWHEAD PHARMACEUTICALS, INC. 163
14.6.1 COMPANY SNAPSHOT 163
14.6.2 REVENUE ANALYSIS 163
14.6.3 PRODUCT PORTFOLIO 164
14.6.4 RECENT DEVELOPMENTS 164
14.7 ARBUTUS BIOPHARMA 165
14.7.1 COMPANY SNAPSHOT 165
14.7.2 REVENUE ANALYSIS 165
14.7.3 PRODUCT PORTFOLIO 166
14.7.4 RECENT UPDATES 166
14.8 AUROBINDO PHARMA 167
14.8.1 COMPANY SNAPSHOT 167
14.8.2 REVENUE ANALYSIS 167
14.8.3 PRODUCT PORTFOLIO 168
14.8.4 RECENT UPDATES 168
14.9 LUPIN PHARMACEUTICALS, INC. 169
14.9.1 COMPANY SNAPSHOT 169
14.9.2 PRODUCT PORTFOLIO 169
14.9.3 RECENT UPDATES 170
14.10 MERCK & CO., INC., 171
14.10.1 COMPANY SNAPSHOT 171
14.10.2 REVENUE ANALYSIS 171
14.10.3 PRODUCT PORTFOLIO 172
14.10.4 RECENT DEVELOPMENTS 172
14.11 NOVARTIS AG 173
14.11.1 COMPANY SNAPSHOT 173
14.11.2 REVENUE 173
14.11.3 PRODUCT PORTFOLIO 174
14.11.4 RECENT DEVELOPMENT 174
14.12 TEVA PHARMACEUTICAL INDUSTRIES 175
14.12.1 COMPANY SNAPSHOT 175
14.12.2 PRODUCT PORTFOLIO 175
14.12.3 RECENT DEVELOPMENTS 175
14.13 ZYDUS PHARMACEUTICALS, INC. 176
14.13.1 COMPANY SNAPSHOT 176
14.13.2 PRODUCT PORTFOLIO 176
14.13.3 REVENUE 177
14.13.4 RECENT DEVELOPMENT 177
15 QUESTIONNAIRE 178
16 RELATED REPORTS 180